Form D · Biotechnology
Blaze Bioscience, Inc.
Seattle, WA · CIK 0001532854
Offering snapshot reported Oct 21, 2024 · SEC filing
- Reported sold
- $8.06M Offering amount: $20M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2024 | Initial | $8,060,000 | No comparison | 2 | SEC filing |
| Oct 21, 2024 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Oct 21, 2024 | Initial | $15,000,000 | No comparison | 6 | SEC filing |
| Oct 21, 2024 | Initial | $25,000,000 | No comparison | 3 | SEC filing |
| Apr 8, 2020 | Amendment | $20,230,000 | $15,230,000vs Feb 14, 2019 | 38 | SEC filing |
| Feb 14, 2019 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| May 15, 2018 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Oct 10, 2017 | Initial | $16,108,197 | No comparison | 32 | SEC filing |
| Jun 22, 2017 | Initial | $554,000 | No comparison | 5 | SEC filing |
| Jan 12, 2016 | Initial | $991,000 | No comparison | 8 | SEC filing |
| Jun 25, 2015 | Amendment | $9,711,998 | $85,400vs Jun 26, 2014 | 27 | SEC filing |
| Jun 26, 2014 | Amendment | $9,626,598 | $1,546,198vs Jun 27, 2013 | 23 | SEC filing |
| Jun 27, 2013 | Initial | $8,080,400 | No comparison | 5 | SEC filing |
| Jun 19, 2012 | Initial | $6,378,179 | No comparison | 19 | SEC filing |
| Oct 17, 2011 | Initial | $725,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-527368
Source: Form D, filed Oct 21, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven R. Daly | Director, Executive |
| Heather L. Franklin | Director |
| Lawrence Patrick Hughes | Director |
| Mary Ellen Hughes | Director |
| Claudia Jochheim | Executive |
| Ludmila R. Lobanova | Executive |
| Dennis Miller | Executive |
| Julia Novak | Executive |
| Jan K. Ohrstrom | Director |
| James Olson | Director |
| James C. Towne | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
530 Fairview Avenue N. Suite 1400
Seattle, WA, 98109
Seattle, WA, 98109